{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:01:55Z","timestamp":1775570515410,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"DOI":"10.7759\/cureus.102783","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T20:08:04Z","timestamp":1769976484000},"source":"Crossref","is-referenced-by-count":1,"title":["Statin-Induced Necrotizing Autoimmune Myositis Presenting With Progressive Limb-Girdle Weakness Following Low-Dose Atorvastatin Use"],"prefix":"10.7759","author":[{"given":"Layla","family":"Annous","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2023.04.002","article-title":"Statins utilization trends and expenditures in the U.S. before and after the implementation of the 2013 ACC\/AHA guidelines","volume":"31","author":"Matyori A","year":"2023","unstructured":"Matyori A, Brown CP, Ali A, Sherbeny F. Statins utilization trends and expenditures in the U.S. before and after the implementation of the 2013 ACC\/AHA guidelines. Saudi Pharm J. 2023, 31:795-800. 10.1016\/j.jsps.2023.04.002","journal-title":"Saudi Pharm J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3350","article-title":"Statin-induced autoimmune necrotizing myositis-A single-center case series highlighting this potentially life-threatening but treatable condition","volume":"8","author":"Jasim M","year":"2020","unstructured":"Jasim M, Sapkota H, Timmons M, Manfredonia F, Pohl U, Barkham N. Statin-induced autoimmune necrotizing myositis-A single-center case series highlighting this potentially life-threatening but treatable condition. Clin Case Rep. 2020, 8:3374-8. 10.1002\/ccr3.3350","journal-title":"Clin Case Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2022.114108","article-title":"Statin-induced necrotizing autoimmune myopathy: a systematic review","volume":"60","author":"Somagutta MK","year":"2022","unstructured":"Somagutta MK, Shama N, Pormento MK, et al.. Statin-induced necrotizing autoimmune myopathy: a systematic review. Reumatologia. 2022, 60:63-9. 10.5114\/reum.2022.114108","journal-title":"Reumatologia"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/08971900211040291","article-title":"Statin-associated autoimmune myopathy: review of the literature","volume":"36","author":"Barrons R","year":"2023","unstructured":"Barrons R. Statin-associated autoimmune myopathy: review of the literature. J Pharm Pract. 2023, 36:383-93. 10.1177\/08971900211040291","journal-title":"J Pharm Pract"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinme.2024.100217","article-title":"Statin-induced, immune-mediated necrotising myopathy triggered by malignancy successfully treated with immunosuppression","volume":"24","author":"Abouelazm A","year":"2024","unstructured":"Abouelazm A, Philops K, Amine A, Golam Y. Statin-induced, immune-mediated necrotising myopathy triggered by malignancy successfully treated with immunosuppression. Clin Med (Lond). 2024, 24:100217. 10.1016\/j.clinme.2024.100217","journal-title":"Clin Med (Lond)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/6550473","article-title":"Statin-induced necrotizing autoimmune myopathy: case report of a patient under chronic treatment","volume":"2023","author":"Bellofatto IA","year":"2023","unstructured":"Bellofatto IA, Sessarego M, Tirandi A, et al.. Statin-induced necrotizing autoimmune myopathy: case report of a patient under chronic treatment. Case Rep Med. 2023, 2023:6550473. 10.1155\/2023\/6550473","journal-title":"Case Rep Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1440206","article-title":"Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations","volume":"14","author":"Selva-O'Callaghan A","year":"2018","unstructured":"Selva-O'Callaghan A, Alvarado-Cardenas M, Pinal-Fern\u00e1ndez I, et al.. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol. 2018, 14:215-24. 10.1080\/1744666X.2018.1440206","journal-title":"Expert Rev Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-1578","article-title":"Hypothyroid myopathy with periodic paralysis as the main symptom: a case report and literature review","volume":"9","author":"Lin N","year":"2020","unstructured":"Lin N, Wang J, Liao W, Wen Y. Hypothyroid myopathy with periodic paralysis as the main symptom: a case report and literature review. Ann Palliat Med. 2020, 9:3698-704. 10.21037\/apm-20-1578","journal-title":"Ann Palliat Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48463","article-title":"Inflammatory myositis following statin use in a patient with untreated hypothyroidism","volume":"15","author":"Renteria M","year":"2023","unstructured":"Renteria M, Jilani M, Brockman MJ, Davis HE. Inflammatory myositis following statin use in a patient with untreated hypothyroidism. Cureus. 2023, 15:e48463. 10.7759\/cureus.48463","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28114","article-title":"Management of immune-mediated necrotizing myopathy","volume":"70","author":"Suh J","year":"2024","unstructured":"Suh J, Amato AA. Management of immune-mediated necrotizing myopathy. Muscle Nerve. 2024, 70:166-72. 10.1002\/mus.28114","journal-title":"Muscle Nerve"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2022.04.017","article-title":"Epidemiological and genetic features of anti-3\u2011hydroxy-3-methylglutaryl-CoA reductase necrotizing myopathy: single-center experience and literature review","volume":"101","author":"Prieto-Pe\u00f1a D","year":"2022","unstructured":"Prieto-Pe\u00f1a D, Ocejo-Vinyals JG, Mazariegos-Cano J, et al.. Epidemiological and genetic features of anti-3\u2011hydroxy-3-methylglutaryl-CoA reductase necrotizing myopathy: single-center experience and literature review. Eur J Intern Med. 2022, 101:86-92. 10.1016\/j.ejim.2022.04.017","journal-title":"Eur J Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16668","article-title":"A case of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myopathy associated with advanced cervical carcinoma","volume":"43","author":"Saillant A","year":"2023","unstructured":"Saillant A, Rasclard M, Gaume JB, Souchaud O, Bainaud M. A case of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myopathy associated with advanced cervical carcinoma. Anticancer Res. 2023, 43:4723-7. 10.21873\/anticanres.16668","journal-title":"Anticancer Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC international workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies, Zandvoort, the Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach Y","year":"2018","unstructured":"Allenbach Y, Mammen AL, Benveniste O, Stenzel W. 224th ENMC international workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies, Zandvoort, the Netherlands, 14-16 October 2016. Neuromuscul Disord. 2018, 28:87-99. 10.1016\/j.nmd.2017.09.016","journal-title":"Neuromuscul Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2023-256956","article-title":"Statin-induced debilitating weakness and myopathy","volume":"17","author":"Ademi B","year":"2024","unstructured":"Ademi B, Folker J, Rothwell WB. Statin-induced debilitating weakness and myopathy. BMJ Case Rep. 2024, 17:6. 10.1136\/bcr-2023-256956","journal-title":"BMJ Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6120424","article-title":"Severe anti-HMG-CoA reductase necrotizing autoimmune myopathy secondary to statin use","volume":"2022","author":"Pulipati P","year":"2022","unstructured":"Pulipati P, Reddy JK, Husain SA. Severe anti-HMG-CoA reductase necrotizing autoimmune myopathy secondary to statin use. Case Rep Rheumatol. 2022, 2022:6120424. 10.1155\/2022\/6120424","journal-title":"Case Rep Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.8563","article-title":"An atorvastatin-induced positive anti-HMGCR immune-mediated necrotizing myopathy case","volume":"12","author":"Chaisrimaneepan N","year":"2024","unstructured":"Chaisrimaneepan N, Thongpiya J, Yingchoncharoen P, Saowapa S. An atorvastatin-induced positive anti-HMGCR immune-mediated necrotizing myopathy case. Clin Case Rep. 2024, 12:e8563. 10.1002\/ccr3.8563","journal-title":"Clin Case Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40552","article-title":"Chronic anti-HMG-CoA reductase positive necrotizing myositis with remote exposure to statins","volume":"15","author":"Salar T","year":"2023","unstructured":"Salar T, Jimenez M, Hameed M, Ocon A. Chronic anti-HMG-CoA reductase positive necrotizing myositis with remote exposure to statins. Cureus. 2023, 15:e40552. 10.7759\/cureus.40552","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12954","article-title":"MRI and muscle imaging for idiopathic inflammatory myopathies","volume":"31","author":"Malartre S","year":"2021","unstructured":"Malartre S, Bachasson D, Mercy G, Sarkis E, Anquetil C, Benveniste O, Allenbach Y. MRI and muscle imaging for idiopathic inflammatory myopathies. Brain Pathol. 2021, 31:e12954. 10.1111\/bpa.12954","journal-title":"Brain Pathol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40825","article-title":"From studio to rehab: a debilitating form of anti-HMGCR myopathy","volume":"15","author":"Anim-Koranteng C","year":"2023","unstructured":"Anim-Koranteng C, Akpoigbe O, Miller M, Averbukh Y. From studio to rehab: a debilitating form of anti-HMGCR myopathy. Cureus. 2023, 15:e40825. 10.7759\/cureus.40825","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/447959-statin-induced-necrotizing-autoimmune-myositis-presenting-with-progressive-limb-girdle-weakness-following-low-dose-atorvastatin-use","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T20:08:04Z","timestamp":1769976484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/447959-statin-induced-necrotizing-autoimmune-myositis-presenting-with-progressive-limb-girdle-weakness-following-low-dose-atorvastatin-use"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.102783","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}